Given the observation by Rothchild et al. (22) that GM-CSF and IFN-γ additively affect M. tuberculosis growth, it is possible that GM-CSF–IFN-γ coadministration would lower the IFN-γ minimal effective dose (i.e., maintain IFN-γ efficacy as an adjunct TB therapy) while also attenuating its negative side effects. The gene discussed is IFNG; the disease is tuberculosis.